Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer

Overview of attention for article published in Breast Cancer Research and Treatment, September 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

patent: 4 patents

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 52 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy

Grant US-11851709-B2

United States of America

Pathology prognosis method

Grant US-11306361-B2

United States of America

Method for predicting conditions

Application FR-3038986-A1

France

PATHOLOGY PROGNOSIS METHOD

Application WO-2017009588-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.